Literature DB >> 19948518

Effects of dexamethasone on pulmonary and renal functions in patients undergoing CABG with cardiopulmonary bypass.

Elsayed Elmistekawy, Hesham El-Serogy.   

Abstract

UNLABELLED: This study evaluates whether dexamesathone in patients undergoing CABG using CPB results in better renal and pulmonary outcome.
METHODS: 100 patients were randomized to receive either placebo or dexamethasone (1 mg/ kg, at induction of anesthesia and 0.5 mg/kg 8 h later).
RESULTS: The differences regarding pulmonary parameters over times were significant in relation to measurements taken 10 minutes after intubation within groups; nevertheless, differences were significant between groups only at 12, 24 hours for A-a O(2) gradient, respiratory index, PaO(2)/FiO(2) ratio. Dexamethasone had no effect on extubation time. Creatinine clearance, urinary micro albumin excretion and (NAG) levels were comparable in both the groups. The dexamethasone treated patients were more likely to have hyperglycemia.
CONCLUSIONS: Dexamethasone offers no renal protective effect and the drug is associated with significant improvement in A-a O(2) gradient, respiratory index, PaO(2)/FiO( 2) at 12, 24 hours postoperatively and had no effect on extubation time and lung compliance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948518     DOI: 10.1177/1089253209351598

Source DB:  PubMed          Journal:  Semin Cardiothorac Vasc Anesth        ISSN: 1089-2532


  7 in total

Review 1.  Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base.

Authors:  R Clive Landis; Jeremiah R Brown; David Fitzgerald; Donald S Likosky; Linda Shore-Lesserson; Robert A Baker; John W Hammon
Journal:  J Extra Corpor Technol       Date:  2014-09

2.  Role of corticosteroids during cardiopulmonary bypass.

Authors:  Judith L Kristeller; Arthur Jankowski; Travis Reinaker
Journal:  Hosp Pharm       Date:  2014-03

3.  Meta-Analysis: Shouldn't Prophylactic Corticosteroids be Administered During Cardiac Surgery with Cardiopulmonary Bypass?

Authors:  Tianci Chai; Xinghui Zhuang; Mengyue Tian; Xiaojie Yang; Zhihuang Qiu; Shurong Xu; Meiling Cai; Yanjuan Lin; Liangwan Chen
Journal:  Front Surg       Date:  2022-06-01

4.  The effect of intravenous magnesium sulfate on serum levels of N-terminal pro-brain natriuretic peptide (NT pro-BNP) in elective CABG with cardiopulmonary bypass.

Authors:  Ali Dabbagh; Ehsan Bastanifar; Mahnoosh Foroughi; Samira Rajaei; Ali Asghar Keramatinia
Journal:  J Anesth       Date:  2013-05-04       Impact factor: 2.078

5.  Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions.

Authors:  Ali Dabbagh; Samira Rajaei; Ayad Bahadori Monfared; Ali Asghar Keramatinia; Korosh Omidi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

6.  Acute Effect of Intravenous Administration of Magnesium Sulfate on Serum Levels of Interleukin-6 and Tumor Necrosis Factor-α in Patients Undergoing Elective Coronary Bypass Graft With Cardiopulmonary Bypass.

Authors:  Parastou Aryana; Samira Rajaei; Abdolhamid Bagheri; Forouzan Karimi; Ali Dabbagh
Journal:  Anesth Pain Med       Date:  2014-06-17

7.  Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass.

Authors:  Ben Gibbison; José Carlos Villalobos Lizardi; Karla Isis Avilés Martínez; Daniel P Fudulu; Miguel Angel Medina Andrade; Giordano Pérez-Gaxiola; Alvin Wl Schadenberg; Serban C Stoica; Stafford L Lightman; Gianni D Angelini; Barnaby C Reeves
Journal:  Cochrane Database Syst Rev       Date:  2020-10-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.